Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation in Acute Ischemic Stroke (SeeBCI)
Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation Training in Patients With Acute Ischemic Stroke: The SeeBCI Study
This is a single-center, prospective, randomized, sham-controlled pilot clinical study designed to evaluate the efficacy, safety, and feasibility of early non-invasive electroencephalography-based brain-computer interface (EEG-BCI) rehabilitation training in patients with acute ischemic stroke.
Eligible participants are adults aged 18 to 80 years with acute ischemic stroke, unilateral upper extremity motor impairment on the dominant-hand side, a baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score of 10 to 50, and confirmed clinical stability 48 to 72 hours after stroke onset.
Participants will be randomly assigned in a 1:1 ratio to receive either real EEG-BCI training plus standard early rehabilitation or sham BCI training plus standard early rehabilitation. Both groups will receive 10 days of training, with two sessions per day and approximately 30 minutes per session.
The primary outcome is the change in FMA-UE score from baseline to 30 days after randomization. Secondary outcomes include changes in FMA-UE, Action Research Arm Test (ARAT), National Institutes of Health Stroke Scale (NIHSS), Modified Barthel Index (MBI), and modified Rankin Scale (mRS). Safety outcomes include symptomatic intracranial hemorrhage, any intracranial hemorrhage, neurological deterioration, seizures, falls, cardiovascular events, and training-related adverse events.
This pilot study aims to provide preliminary evidence regarding the feasibility, safety, and potential efficacy of early EEG-BCI rehabilitation after acute ischemic stroke and to inform the design of future multicenter randomized controlled trials.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Wang Chen, MD
- 電話番号:+86 531 68773274
- メール:chenwang@sph.com.cn
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18 to 80 years.
- Diagnosis of acute ischemic stroke.
- Stroke onset to randomization within 48 to 72 hours.
- Meets predefined clinical stability criteria before randomization.
- Unilateral upper extremity motor impairment on the dominant-hand side.
- Baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score between 10 and 50.
- Pre-stroke modified Rankin Scale (mRS) score ≤2.
- Written informed consent obtained from the participant or legally authorized representative.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Real EEG-BCI Training + Standard Early Rehabilitation
Participants will receive real electroencephalography-based brain-computer interface (EEG-BCI) training combined with standard early rehabilitation. The EEG-BCI training uses upper extremity motor imagery or motor attempt tasks with real-time decoding of motor intention and virtual hand feedback. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total). |
Non-invasive EEG-based brain-computer interface training combined with standard early rehabilitation. The intervention includes EEG signal acquisition, motor intention decoding, and real-time virtual hand feedback. Participants perform upper extremity motor imagery or motor attempt tasks. Training is delivered twice daily for approximately 30 minutes per session for 10 consecutive days. Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions. |
|
偽コンパレータ:Sham BCI Training + Standard Early Rehabilitation
Participants will receive sham BCI training combined with standard early rehabilitation. The sham procedure will match the real EEG-BCI training in appearance, frequency, duration, and workflow, but the feedback will not be generated by real-time EEG-based motor intention decoding. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total). |
Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions. Sham BCI training designed to maintain participant masking. The procedure matches real EEG-BCI training in device setup, training environment, frequency, duration, and workflow, but the feedback is not linked to the participant's real-time EEG motor intention decoding. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score From Baseline to Day 30
時間枠:Baseline to Day 30 after randomization
|
The primary outcome is the change in FMA-UE score from baseline (T0) to 30 days after randomization. The FMA-UE evaluates upper extremity motor function after stroke, with scores ranging from 0 to 66. Higher scores indicate better upper extremity motor function. Change score is calculated as the FMA-UE score at Day 30 minus the baseline FMA-UE score. |
Baseline to Day 30 after randomization
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score
時間枠:Baseline, Day 10, Day 30, and Day 90
|
Upper extremity motor function will be assessed using the FMA-UE. The total score ranges from 0 to 66, with higher scores indicating better motor function. |
Baseline, Day 10, Day 30, and Day 90
|
|
Action Research Arm Test (ARAT) Score
時間枠:Baseline, Day 30, and Day 90
|
Upper extremity activity performance will be assessed using the ARAT. The total score ranges from 0 to 57, with higher scores indicating better upper limb functional ability. |
Baseline, Day 30, and Day 90
|
|
National Institutes of Health Stroke Scale (NIHSS) Score
時間枠:Baseline, Day 10, and Day 30
|
Neurological impairment will be assessed using the NIHSS. Scores range from 0 to 42, with higher scores indicating greater neurological deficit. |
Baseline, Day 10, and Day 30
|
|
Modified Rankin Scale (mRS) Score
時間枠:Day 90
|
Global functional outcome will be assessed using the modified Rankin Scale. Scores range from 0 to 6, with higher scores indicating greater disability. |
Day 90
|
|
Modified Barthel Index (MBI) Score
時間枠:Day 30 and Day 90
|
Activities of daily living will be assessed using the Modified Barthel Index. Higher scores indicate better functional independence. |
Day 30 and Day 90
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Training Completion Rate
時間枠:During the 10-day intervention period
|
Feasibility outcome defined as the proportion of completed EEG-BCI or sham BCI training sessions among the planned 20 sessions. |
During the 10-day intervention period
|
|
Effective Training Duration
時間枠:During the 10-day intervention period
|
Feasibility outcome defined as the cumulative duration of completed valid BCI training sessions during the intervention period. |
During the 10-day intervention period
|
|
EEG Signal Quality and BCI Performance Metrics
時間枠:During the 10-day intervention period
|
Feasibility outcome assessing EEG acquisition quality and available BCI performance metrics, including signal quality and classification accuracy when available. |
During the 10-day intervention period
|
|
Follow-up completion rate
時間枠:Through Day 90
|
Feasibility outcome defined as the proportion of randomized participants who complete scheduled outcome assessments through Day 90. |
Through Day 90
|
|
Protocol deviation rate
時間枠:From randomization through Day 90
|
Feasibility outcome defined as the proportion of participants with one or more protocol deviations. |
From randomization through Day 90
|
|
Incidence of symptomatic intracranial hemorrhage
時間枠:From baseline through Day 90
|
Safety outcome defined as the occurrence of symptomatic intracranial hemorrhage after randomization. |
From baseline through Day 90
|
|
Incidence of any intracranial hemorrhage
時間枠:From baseline through Day 90
|
Safety outcome defined as the occurrence of any type of intracranial hemorrhage after randomization. |
From baseline through Day 90
|
|
Incidence of neurological deterioration
時間枠:From baseline through Day 90
|
Safety outcome defined as clinically relevant neurological worsening after randomization, such as an increase in NIHSS score of 4 or more points without another clear explanation. |
From baseline through Day 90
|
|
Incidence of seizures
時間枠:From baseline through Day 90
|
Safety outcome defined as the occurrence of seizure events after randomization. |
From baseline through Day 90
|
|
Incidence of Falls or Injuries
時間枠:From baseline through Day 90
|
Safety outcome defined as the occurrence of falls during the study period. |
From baseline through Day 90
|
|
Incidence of Cardiovascular and Vital Sign Events
時間枠:From baseline through Day 90
|
Safety outcome defined as the occurrence of clinically relevant blood pressure instability or cardiac arrhythmia events during the study period. |
From baseline through Day 90
|
|
Incidence of training-related discomfort
時間枠:During the 10-day intervention period
|
Safety outcome defined as the occurrence of training-related discomfort, including fatigue, headache, dizziness, nausea, skin irritation, or other discomfort associated with the intervention. |
During the 10-day intervention period
|
|
Incidence of serious adverse events
時間枠:From baseline through Day 90
|
Safety outcome defined as the occurrence of serious adverse events (SAEs), including death, life-threatening events, hospitalization or prolongation of hospitalization, persistent or significant disability, or other medically important events. |
From baseline through Day 90
|
協力者と研究者
捜査官
- 主任研究者:QinJian Sun, MD、Shandong Provincial Hospital
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。